The ability for TDAG8 gene expression to provide a disadvantage for U937 cell proliferation, tumor growth, and metastasis confirmed that TDAG8 gene expression provides a disadvantage for blood cancer progression. The gene discussed is GPR65; the disease is hematopoietic and lymphoid system neoplasm.